Laurus Labs Ltd. (IN:LAURUSLABS)
:LAURUSLABS
LAURUSLABS Stock Chart & Stats
₹1107.05
-₹1.35(-0.22%)
At close: 4:00 PM EST
₹1107.05
-₹1.35(-0.22%)
Day’s Range― - ―
52-Week Range₹517.05 - ₹1,140.90
Previous CloseN/A
Volume1.25M
Average Volume (3M)107.31K
Market Cap
₹544.88B
Enterprise Value₹565.66B
Total Cash (Recent Filing)₹633.80M
Total Debt (Recent Filing)₹22.12B
Price to Earnings (P/E)59.4
Beta1.08
Next Earnings
Apr 23, 2026EPS Estimate
4.89Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)4.70
Shares Outstanding539,856,570
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.23
Price to Sales (P/S)5.82
P/FCF Ratio-821.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,225.00Price Target Upside10.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)16.05
Revenue Forecast (FY)₹68.38B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit revenue growth reflects expanding commercial traction across APIs, FDF and CDMO lines. Durable top-line expansion supports scale economics, funds reinvestment into capacity and R&D, and underpins medium-term earnings recovery if maintained.
Gross Margin SustainabilityA strong gross margin indicates persistent production efficiencies and some pricing power in manufacturing. This margin durability helps absorb tender pricing pressures, supports reinvestment in plants, and bolsters long-term unit economics across export markets.
Diversified Business ModelMultiple durable revenue streams—APIs, FDF and CDMO—plus ARV specialization reduce single-product/customer dependence. Structural diversification smooths demand cyclicality, supports recurring institutional contracts, and strengthens resilience over the next several months.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow driven by heavy capex limits the firm's ability to self-fund expansion or payouts. Over 2–6 months this raises refinancing and liquidity risk, constrains strategic flexibility and heightens sensitivity to any downturns in cash generation.
Rising Liabilities / LeverageAn increasing liabilities trend and declining equity ratio indicate worsening capital structure and moderate but growing leverage. That reduces financial flexibility, increases interest/service burdens, and heightens vulnerability to margin pressure or interest rate moves over the medium term.
Net Profit Margin CompressionFalling net margins from rising expenses erode retained earnings and ROE, weakening the company's ability to convert revenue into durable profits. If cost pressures persist, margin recovery will require pricing, mix shifts, or efficiency gains to restore long-term profitability.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹517.05 and its highest was ₹1140.90 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹544.88B.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Apr 23, 2026 which is in 24 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jan 23, 2026. The company reported ₹4.7 earnings per share for the quarter, beating the consensus estimate of ₹3.675 by ₹1.025.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Notavailable dividend of ₹0.8 which represents an annual dividend yield of 0.15%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 4.89.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 539,856,570 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹4.7 in its last earnings report, beating expectations of ₹3.675. Following the earnings report the stock price went up 1.214%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,225.00
▲(10.65% Upside)
Technical Analysis
Biocon Limited
―
Gland Pharma Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
―